News In Brief
This article was originally published in The Gray Sheet
Executive SummaryBard buys Medivance
You may also be interested in...
Executives recently described a series of upcoming product rollouts, including a new temperature management device.
Recent approvals and launches include St. Jude Medical’s EnligHTN renal denervation system for hypertension and Zeltiq Aesthetics’ expanded CoolSculpting clearance for fat reduction.
Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.